Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
Phase 2
Completed
- Conditions
- Non-small Cell Lung CancerNeoplasm MetastasisLung Cancer
- Interventions
- First Posted Date
- 2005-01-19
- Last Posted Date
- 2010-10-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 50
- Registration Number
- NCT00101920
Effectiveness and Safety of Enbrel® (Etanercept) in Rheumatoid Arthritis Subjects Who Have Failed Remicade® (Infliximab)
Phase 4
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2004-12-17
- Last Posted Date
- 2009-11-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 200
- Registration Number
- NCT00099554
Study Evaluating Darbepoetin Alfa in Subjects With Chronic Kidney Disease (CKD) Receiving Dialysis
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2009-05-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 110
- Registration Number
- NCT00096915
Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis
- First Posted Date
- 2004-11-08
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 227
- Registration Number
- NCT00095498
Darbepoetin Alfa Administered Once Every 4 Weeks in the Treatment of Subjects With Anemia of Cancer
Phase 2
Completed
- Conditions
- Anemia
- First Posted Date
- 2004-11-03
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 220
- Registration Number
- NCT00095277
A Study of Darbepoetin Alfa in Anemic Subjects With Low Risk Myelodysplastic Syndrome
Phase 2
Completed
- Conditions
- Myelodysplastic Syndromes
- First Posted Date
- 2004-11-03
- Last Posted Date
- 2010-01-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 209
- Registration Number
- NCT00095264
Pegfilgrastim Given Same Day As or Day After Carboplatin and Docetaxel in Advanced Metastatic Non-Small Cell Lung Cancer (NSCLC)
Completed
- Conditions
- Lung CancerNon-Small Cell Lung Cancer
- Interventions
- Other: PI Discretion
- First Posted Date
- 2004-10-27
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 90
- Registration Number
- NCT00094822
Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Completed
- Conditions
- Lung CancerNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2004-10-27
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 51
- Registration Number
- NCT00094835
Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
Phase 2
Completed
- Conditions
- Colon CancerColorectal CancerRectal Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2004-10-26
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Amgen
- Target Recruit Count
- 252
- Registration Number
- NCT00094809
Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis
Phase 3
Completed
- Conditions
- Kidney DiseaseChronic Kidney Disease
- First Posted Date
- 2004-10-20
- Last Posted Date
- 2013-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 400
- Registration Number
- NCT00094484
© Copyright 2025. All Rights Reserved by MedPath